Kornimate/medical-research-clean huggingface dataset:
effect of posture and breathing exercises in forward head posture

Conditions: Forward Head Posture

Summary: this study aims to compare the effects of postural exercises with and without breathing exercises in the subjects having forward head posture.

forward head posture (fhp) is a prevalent postural deviation that can occur in individuals of various age groups, spanning from childhood to old age. it manifests as an anterior positioning of the head in relation to the neck in the sagittal plane. . fhp is commonly associated with the excessive extension of the upper cervical spine (c1-c3) and flexion of the lower cervical spine (c4-c7). a common method to diagnose forward head posture is by measuring craniovertebral angle i.e. if cva\<49 than fhp is positive. in many cases faulty postures are linked with different musculoskeletal conditions as well as breathing difficulties. forward head posture specifically impairs the mobility and functionality of the diaphragm, resulting in inefficient contraction of abdominal muscles and reduced lung capacity. a randomized clinical trial will be conducted so that we can rule out proper treatment protocol for forward head posture. for this randomized clinical trial, 36 participants having forward head posture will be recruited from sehat medical complex and shalamar hospitals lahore by nonprobability convenient sampling. participants will divide in two groups a and b by randomization. group a will be given both exercise regimes of postural exercises and breathing exercises while group b will be given with only postural exercise protocol. pain, rom and craniovertebral angle will be assessment before the treatment start, after 5 weeks and at the end of treatment after 10 weeks. after the collection of data in 8 months, statistical analysis using spss version 21, will be done to summarize the results.

Eligibility criteria:
inclusion criteria: * individuals with 20 to 35 years of age, both male and female * individuals with cva \<49. exclusion criteria: * history of surgery of thorax or spine or both. * traumatic neck injury. * acute or chronic neuro-muscular pain. * clinical deformity present in thoracic cage or spine

Keywords: breathing exercises
extended release tacrolimus (advagraf®) in severe adult atopic dermatitis patients

Conditions: Atopic Dermatitis

Summary: to evaluate the clinical efficacy of the extended release formulation of tacrolimus (advagraf®) in patients with severe atopic dermatitis, who can not be treated adequately with cyclosporine a because of side effects and/or non-responsiveness.


Eligibility criteria:
inclusion criteria: * adult patients with severe atopic dermatitis, uncontrolled by topical treatment (indication for oral immunosuppressive drugs), who are unresponsive to cyclosporin a, or in which treatment was discontinued because of side effects. exclusion criteria: * concomitant use of other oral immunosuppressive drugs and/or uv light therapy * preexisting abnormalities in liver function, kidney function or haematological abnormalities * history of malignancy within the last 5 years * uncontrolled hypertension * pregnancy or lactation; wish for pregnancy during the treatment period * infections requiring continued therapy * known positivity for hiv * evidence of drug and/or alcohol abuse
evaluation of the satisfaction of the patients operated for a mild hyperplasie of the prostate by laser in ambulatory surgery

Conditions: Prostatic Hyperplasia

Summary: every year more than 70 000 interventions for prostatic adenoma are realized. several type of surgery are realized going of the ambulatory to longer hospital lengths of stay. there are also several techniques.however it appears that ambulatory surgery is less costly. the arguments of surgeons are patients reluctance or the difficulty to manage in case of complication. the aim of the study is to show that there is a good acceptance from patient with a good level of satisfaction at day 30.


Eligibility criteria:
inclusion criteria: * age\> 18 * patient with benign prostatic hyperplasia * ambulatory eligibility exclusion criteria: * recused for ambulatory surgery * patients operated by surgeons not having ended their learning curve.
ulcer bleeding after band ligation of esophageal varices

Conditions: Esophageal Varices

Summary: primary outcomes: assessment of incidence , risk factors and prognosis of post-banding ulcer bleeding following evl in patients with liver cirrhosis. secondary outcomes: minimize post-banding ulcer bleeding

esophageal variceal bleeding represents the most vital complication among patients with liver cirrhosis at rate of 5-15% per year. endoscopic variceal ligation (evl), either used as therapeutic in emergency or as prophylactic, is one of the best modalities used in ev treatment. the procedure is effective and generally safe. after banding, a superficial ulcer is formed, which usually heals in 2-3 weeks. the main complications of variceal banding are pain, dysphagia, fever, bleeding during the procedure and post banding ulcer bleeding (pbub). the prevalence of pbub is reported to be 3.6-15% . rebleeding can be fatal, and is mainly resulted from early spontaneous slippage of the rubber bands, before occlusion of the varix with a mature thrombus, leaving an unhealed ulcer . the time frame of variceal rebleeding can be divided into very early rebleeding (within 5 days of acute bleeding), early rebleeding (within 6 weeks of acute bleeding), and delayed rebleeding. previous reports showed that early rebleeding ranged from 30% to 40% within the first 6 weeks, and was significantly associated with the risk of death within 6 weeks. therefore, the aim of this research is assessment of incidence , risk factors and prognosis of post-banding ulcer bleeding following evl in patients with liver cirrhosis, in order to minimize post-banding ulcer bleeding.

Eligibility criteria:
inclusion criteria: 1. patients' age is 18 years or above. 2. patient who are diagnosed with esophageal varices by upper endoscopy. 3. patient who are fit for surgery to undergo endoscopic banding procedure. exclusion criteria: 1. pediatric patients. 2. patient refuse to participate at this study
brijjit® for wound closure in gender affirming mastectomies

Conditions: Mastectomy

Summary: this study will evaluate the use of brijjit® for wound closure in individuals undergoing bilateral double incision gender affirming mastectomies with a single surgeon (rachel bluebond-langner, md). the study will be a randomized prospective interventional study utilizing internal controls (one side of chest receives intervention, other serves as control). primary endpoints will include scar appearance/quality and wound complications

the hypothesis of this study is that the use of brijjit® fmtb will result in improved scar outcomes as measured by both patient and treating physician as compared to traditional suture based wound closure methods. as mentioned, at present there is no standard of care for wound closure following double incision gam, therefore an internal control approach will be taken with patients serving as their own controls. this will be achieved by having one side of the chest receive the of brijjit® fmtb (intervention) in addition to suture closure of the skin, while the other side will be closed with traditional methods, a combination of sutures and steri-stripstm (control).

Eligibility criteria:
inclusion criteria: * patient self-identifies as transgender or gender expansive * patient will undergo primary bilateral double incision mastectomy at nyulh * all clinical criteria to be eligible for primary mastectomy must be met * ability to care for donor site and adhere to wound therapy (either solo or with care-giver assistance) * willingness to return for scheduled follow-up visits through 1 year post-operatively * 18 years of age or older * english speaking exclusion criteria: * individuals with previously diagnosed allergies or a history of adverse effects related to adhesives / adhesive tapes * individuals with a history of the following prescription medication use in the last year: accutane, systemic glucocorticoids and/or local glucocorticoids or immunosuppressants (i.e. topical tacrolimus, topical clindamycin etc.) at the intervention site * individuals with a history of significant scarring or adverse scarring (hypertrophic scars or keloid scars) * individuals with pre-existing scars at the gam wound closure site * individuals with a disorder known to negatively affect wound healing (i.e. autoimmune disease, connective tissue disease) * individuals with malnutrition * individuals with a bmi \>30 kg/m2 * individuals with a history of radiation therapy * active smokers or smokeless nicotine use * history of previous mastectomy * patient is actively immunosuppressed i.e. aids (hiv+ acceptable), or systemic immunosuppressants * patients unable to attend post-operative follow-ups in person * patients with a considerable history of medical non-compliance * patient will receive gam not including double incisions (i.e. periareolar)
pre-operative 3-dcrt vs imrt for locally advanced rectal cancer

Conditions: Locally Advanced Rectal Cancer

Summary: the study aims to compare the incidence of acute grade 2 gi toxicity in the control 3-d conformal radiotherapy compared to the intensity modulated radiotherapy (imrt) arm for locally advanced rectal cancer.

pre-operative radiotherapy (rt) or chemo-radiotherapy (crt) is internationally accepted as standard practice in the management of locally advanced rectal cancer. multiple randomised trials have proved pre-operative crt and rt, compared to surgery alone, reduce local recurrence, even prior to optimal surgery, and may improve survival for t3 circumferential resection margin (crm) negative patients. this study aims to determine if 3-dcrt or imrt result in lower incidence of grade 2 gi toxicities. acute toxicities will be assessed weekly during radiotherapy, and at 2 and 4 week post treatment. late toxicities will be assessed at 3, 6, 9, 12, 18, 24 months post treatment, and annually to 10 years.

Eligibility criteria:
inclusion criteria: * patients undergoing pre-operative pelvic chemo-radiotherapy for histologically confirmed rectal adenocarcinoma, with the following staging: ct3n0-2, ct4n0-2, ct(any)n1-2, ct(any)n(any) crm at-risk \[ajcc version v\] * staging / imaging of pelvis with mri, and ct thorax/abdomen * no evidence of metastatic disease * ecog performance status 0 - 2 * age \> or equal to 18 years * provision of written informed consent in line with ich-gcp guidelines exclusion criteria: * previous radiotherapy to the pelvic region * patients in whom induction chemotherapy has been delivered prior to chemo- radiotherapy * history of inflammatory bowel disease * previous hip replacement * previous bowel surgery (excluding procedures/operations which would not result in small bowel adhesions - at the discretion of the principal investigator) * patients with other syndromes/conditions associated with increased radiosensitivity * any other co-existing malignancies within the past 5 years other than non- melanoma skin cancer * pregnancy or lactation at the time of proposed randomisation * evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study or if it is felt by the research / medical team that the patient may not be able to comply with the protocol
analyzing the benefits of using symptoms-jit for in vivo exposure in anxiety disorders

Conditions: Anxiety Disorders; Specific Phobia; Panic Disorder; Agoraphobia; Social Anxiety Disorder

Summary: the aim of this study is to develop and test the efficacy of first-of-its-kind, fully instrumented sensor-based smartphone-guided in-vivo exposure therapy using a just-in-time intervention for anxiety disorder. the main hypotheses are: 1. both treatment conditions (cbt treatment with ive and cbt treatment with ive+symptoms-jit) will show efficacy and no statistically significant differences will be found between them. the efficacy will be determined for the differences in pre-post treatment in the used outcome measures. 2. the therapeutic gains obtained in both treatment conditions (ive and (ive+symptoms-jit) will be maintained at 1-, 6-, and 12-month follow-up periods. 3. both treatment conditions will be efficient, that is, they will be well-valued by patients and therapists. however, ive+symptoms-jit will be preferred and perceived as less aversive than ive. 4. the main barriers for the use of this technology are not technological, but rather attitudinal and they can be identified through qualitative studies.

anxiety disorders are one of the most prevalent psychological problems around the world and if not treated they tend to become chronic. cognitive behavioral therapy (cbt) is the treatment of choice, being the component of in vivo exposure (ive) the central feature. despite its efficacy it is still a hard component to implement for the patients. information and communication technologies (ict) can help assisting and/or applying psychological interventions. the proposed study will fill the existing gap in this sense as it will assess the efficacy of a fully configurable, sensor-guided and location-based (gps) app for the in vivo exposure component. it will also address the shortage of clinical validation studies of mhealth apps thanks to the proposed rct. the study will expand our knowledge about the use of technologies in mental health problems and help improve the effectiveness of exposure therapy.

Eligibility criteria:
inclusion criteria: * being at least 18 years or older. * meeting dsm-5 diagnostic criteria (apa, 2013) for anxiety disorder, specifically specific phobia, agoraphobia, panic disorder and social phobia. * being willing to follow the study conditions. * sign the consent form. exclusion criteria: * having another psychological problem that requires immediate attention. * having current alcohol or drug dependence or abuse, psychosis or severe organic illness. * currently being treated in a similar treatment program. * taking anxiolytics during the study (or in the case of taking them, changing drug or dose during the study).

Keywords: anxiety disorders in vivo exposure app smartphone smartwatch
open label extension in adults with binge eating disorder (bed)

Conditions: Binge Eating Disorder

Summary: to evaluate the safety and tolerability of spd489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (bed) in adults


Eligibility criteria:
inclusion criteria: 1. completion of an antecedent spd489 bed double-blind study 2. subject meets the following diagnostic and statistical manual of mental disorders fourth edition - text revision (dsm-iv-tr) criteria for a diagnosis of bed 3. subject has a body mass index (bmi) of \> or =18 and \< or =45 exclusion criteria: 1. subject has concurrent symptoms of bulimia nervosa or anorexia nervosa. 2. subject is considered a suicide risk or risk to harm others
a phase iii trial evaluating fruquintinib efficacy and safety in 3+ line colorectal cancer patients （fresco)

Conditions: Colorectal Cancer

Summary: fruquintinib administered at 5mg once daily(qd) in 4 weeks treatment cycle (three weeks on and one week off) was well tolerated and demonstrated encouraging preliminary clinical antitumor activity in patients with metastatic colorectal cancer (crc) in phase ib and phase 2 study. this study is aimed to evaluate the efficacy and safety of fruquintinib in the treatment of patients with metastatic crc who have progressed after second line or above standard chemotherapy

this is a randomized, double-blind, placebo-controlled, multicenter phase iii clinical trial to compare the efficacy and safety of fruquintinib plus bsc versus placebo plus bsc in patients with metastatic colorectal cancer who have progressed after second-line or above standard chemotherapy. after checking eligibility criteria, subjects will be randomized into fruquintinib plus bsc group (treatment group) or placebo plus bsc group (control group) in a ration of 2:1. primary efficacy endpoint: overall survival (os). secondary efficacy endpoints: progression free survival (pfs) (according to recist version 1.1), objective response rate (orr), disease control rate (dcr), . safety and tolerance will be evaluated by incidence, severity and outcomes of aes and categorized by severity in accordance with the nci ctc ae version 4.0.

Eligibility criteria:
inclusion criteria: * ≥ 18 and ≤ 75 years of age , with ≥ 40kg * histological or cytological confirmed colorectal cancer * ecog performance status of 0-1 * standard regimen failed or no standard regimen available * adequate hepatic, renal, heart, and hematologic functions * at least one measurable lesion (larger than 10 mm in diameter by spiral ct scan) * signed and dated informed consent * willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure exclusion criteria: * - pregnant or lactating women * any factors that influence the usage of oral administration * evidence of cns metastasis * intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure * abuse of alcohol or drugs * less than 4 weeks from the last clinical trial - previous treatment with vegfr inhibition * disability of serious uncontrolled intercurrence infection * proteinuria ≥ 2+ (1.0g/24hr) * have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness * within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc. * within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or cabg * bone fracture or wounds that was not cured for a long time * coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

Keywords: colorectal cancer
substance use treatment and its role in supporting social cognition

Conditions: Substance Use; Empathy

Summary: this study aims to assess changes in empathy levels before and after residential treatment among individuals with substance use disorders.

despite the lack of a consensus on the conceptualization of empathy among researchers and practitioners, psychologists generally agree that empathy and valuable interpersonal relations are contingent upon the willingness to understand another's perspective as well as share feelings and experiences. adults with a variety of substance use disorders (suds) experience impairments in various facets of empathetic processing compared to healthy controls. impairments in empathy could lead to a weak therapeutic alliance, lower adherence to treatment, and higher relapse rate. furthermore, the therapeutic relationship has been described as one of the strongest predictors of treatment drop-out for patients with suds. in addition, an impaired ability to relate to and understand the affective and mental state of others may contribute to key typologies of patients with suds including, impulsivity, aggression, and antisocial behavior. review of literature emphasizes a need for research into an understudied, yet modifiable factor of empathy in the trajectory of suds. particularly, identifying specific psychotherapeutic techniques capable of improving the expression of empathy in these patients. given the importance of empathetic ability in optimal social functioning, understanding whether empathetic impairments improve with treatment is important to achieve the best treatment outcomes for individuals struggling with suds.this study will help improve the knowledge and understanding of how substance use treatment affects empathy, as measured by gains in empathetic ability in treatment seeking individuals. to date, there are no reported studies that examined the impact of residential su treatment on empathy. the study will be an observational quasi-experimental design that utilizes a pre-test and post-test to examine change in empathy for recently detoxed substance use patients and a follow-up assessment to monitor long term outcomes. the results of this study will further our understanding of treatment's potential role in cultivating a fundamental interpersonal skill, empathy.

Eligibility criteria:
inclusion criteria: * meet criteria for a substance use disorder, receiving treatment at recovery unplugged addiction treatment center, at least 18 years of age. exclusion criteria: * neurological disorder, severe cognitive impairment, comorbid thought disorder such as schizophrenia, failure to complete detox period,

Keywords: substance use, empathy
long-term non-interventional latanoprost study

Conditions: Glaucoma; Ocular Hypertension

Summary: this is a non-interventional, prospective, longitudinal cohort study. a total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. as a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.

at least 40 subjects in each of the following age groups: 1-\<5 years and 5-\<18 years. no minimum required numbers in the \<1 year age group.

Eligibility criteria:
inclusion criteria: * male or female \<18 years of age (neonates must be at least 36 weeks gestational age). * diagnosis of pediatric glaucoma or elevated intraocular pressure. * evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. a signed and dated assent will be required where applicable according to local laws. for treated subjects only: * continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination. for untreated subjects only: * continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; or * no prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period. exclusion criteria: * unable/unwilling to comply with protocol. * pregnant or nursing females at baseline. * for treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).

Keywords: prospective non-interventional longitudinal cohort study